biotechnolog pipelin move focu legaci busi slow initi coverag neutral rate
medic suppli devic md result med-tech later
page analyst certif import disclosur
 pipelin move focu legaci busi slow
initi coverag neutral rate valuat
publish april
messag initi coverag neutral rate valuat rang global diversifi
compani guid revenu pipelin invest focus cardiometabol inflamm
cancer therapeut area success enbrel patent litig otezla acquisit celg/bmi announc key driver
multipl expans rel biopharma peer believ stock current fairli valu base growth profil think investor
requir visibl addit sourc ebit growth current consensu compound-annual-growth-rate time view addit
downsid risk exist current street consensu estim amgn portfolio mature-lifecycl legaci product face brand biosimilar
competit think current early- mid-lifecycl growth product alon may fulli off-set revenu eros declin legaci product
gener posit view late-stag pipelin estim alreadi significantli consensu
valuat rang per share base multipl rang ebit estim
posit weather
publish april
messag updat model outlook reflect impact issu busi updat link includ
follow credit agreement amend suspend net leverag coven new revolv credit facil
establish avail capac total liquid posit free cash defer revenu
avail capac target cost reduct model assum substanti reduct live event held
attend vs prior due primarili impact march pt
page analyst certif import disclosur
balanc sheet risk tabl rais pt
publish april
messag yesterday close announc preliminari revenu yoy well consensu
mid-march shi revis estim view solid result consid recent relat disrupt
manag note substanti inspir procedur postpon sinc viru mitig effort kick gear last month
conjunct pre-announce compani also complet equiti financ believ provid ampl liquid
weather current storm rais price target reiter buy rate
outlook reduc price
publish april
messag updat model price target reflect compani pre-announc updat outlook primarili
ad trend lower ad revenu estim balanc consist outlook demand headwind
come quarter publish link explicit press releas believ revenu heavili skew lower-
profit product segment initi forecast lower price target primarili reflect estim
chang price target base platform segment consist valuat approach peer
 buy secular light end tunnellow
estim rais pt
publish april
messag like retail five n-t oper result quit murki store close present precis re-open cadenc
unclear know consum demand look like re-open addit lower sale volum pressur profit margin
next quarter two said three thing favor one account annual profit year salvag
normalci return halloween valu oper model fare rel well recess lastli like emerg one
secular growth stori result healthi multipl exhibit lower estim rais pt maintain buy
page analyst certif import disclosur
publish april
messag provid updateimpli net outflow million cash past two monthsbut
compani announc price million convert senior note due given high-cost natur transact includ
purchas convert note hedg sale warrant believ yesterday updat highlight level uncertainti exist across
retail updat estim incorpor up-to-d revenu margin forecast addit interest drag associ
convert note offer bottom line expect report net loss
publish april
messag updat estim follow result reiter neutral rate
 takeaway manag call oxbryta
launch impact
publish april
messag takeaway call management includ oxbryta launch trend look posit management extrem pleas
launch reimburs dynam favor still expect broad payor coverag hematologists/scd doc will
use virtual visit evalu patient prescrib oxbryta phone result continu patient growth despit pandem
year suppli oxbryta due earli stockpil ema regulatori updat expect later year pediatr approv next year
believ suffici cash hand reach cash flow-posit statu
page analyst certif import disclosur
pre-announc better acceler demand
publish april
messag today close pre-announc better expect result compani refrain provid updat beyond
comment would provid detail earn confer call schedul april believ current environ pull
forward adopt curv like gener sustain repeat util compani reiter buy rate pt
publish april
messag announc today withdraw previous announc full-year revenu guidanc amid uncertainti due
compani also announc preliminari revenu result like buysid expect consensu number
remind sell-side bring number last coupl week awar us-bas research lab alreadi
prep potenti slowdown mid-march compani mention expect signific impact revenu longer term thesi
remain intact believ could strong year nih fund could tailwind compani
publish april
messag mani food beverag categori continu benefit stock higher rate at-hom consumpt period end
april benefit clearli slow head gener packag food continu see strong consumpt especi prepar meal
soup mac chees cereal beverag categori start see de-stock last especi water head
earn season continu expect strong sale growth across coverag deceler benefit compani especi
page analyst certif import disclosur
publish april
messag kick like messi earn season high note ep yoy came ahead street
estim revenu organ top consensu posit howev medic devic sale came
alreadi reduc expect declin organ basi driven elect procedur deferr wake
outbreak walk key takeaway result relat devic franchis later rest med-tech
neutral appoint new ceo remain track
publish april
messag today neutral announc appoint thoma civik presid chief execut offic member
board director compani compani reiter remain track plan program mileston clinic data
disclosur continu look forward go no-go decis bemarituzumab phase advanc gastric cancer
fight trial futil analysi william ringo serv interim ceo sinc septemb continu chairman board director
guid minim covid-rel impact pharma segment
publish april
messag gmab partner report earn includ net darzalex sale well consensu estim
gmab consensu estim sale provid foundat strong view darzalex-bas combin continu
gain traction myeloma set largest commerci opportun mm remain bullish darzalex longer term gradual frontlin
multipl myeloma penetr continu substanti grow address market opportun term number patient treat durat
potenti reiter buy rate head catalyst-rich
page analyst certif import disclosur
posit ahead cortrophin gel pdufa
publish april
messag arthur przybyl depart presid ceo may year role although surpris departur come
somewhat natur transit point view ahead cortrophin gel pdufa speak manag believ relat
fundament disagr strateg direct compani importantli management reiter full confid approv cortrophin gel
view signific upsid driver share hire extern execut search firm lead search new presid ceo
publish april
today top mind updat guid highlight revenu account add out-performance
cantwel highlight key takeaway confer call compani cfo head ir director data analyt includ recent
retail sale data challeng near-term oper environ well medium-term outlook
publish april
page analyst certif import disclosur
chat util suit ceo april et
ad ndr schedul scroll
firesid chat stabl stori despit uk overhang strong manag bench place see note
taconit miner move idl nt product amidst covid-fallout
duke restor power carolina follow major storm
vogtl case rise yesterday await result
pjm webinar mopr file highlight import unit-specif exempt
page analyst certif import disclosur
inc
page analyst certif import disclosur
page analyst certif import disclosur
primari analyst glen santangelo
page analyst certif import disclosur
page analyst certif import disclosur
primari analyst etzer darout
life scienc tool omic
primari analyst david westenberg cfa
page analyst certif import disclosur
